Prelude Therapeutics Incorporated (PRLD) Tops Q1 EPS by 10c

Prelude Therapeutics Incorporated (NASDAQ: PRLD) reported Q1 EPS of ($0.13), $0.10 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $4.58 million.

For earnings history and earnings-related data on Prelude Therapeutics Incorporated (PRLD) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• MicroVision prices $17 million public offering at $2.50 per unit
• Could Intel return to the red-hot memory market after $20B raise and recent hire?